No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. Japan Adult Leukemia Study Group.

Mitsune Tanimoto

No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. Japan Adult Leukemia Study Group.

Mitsune Tanimoto

Medical School

Research output: Contribution to journal › Article

Original language	English
Pages (from-to)	97-104
Number of pages	8
Journal	Int J Hematol
Volume	70
Issue number	(2)
Publication status	Published - 1999

Cite this

@article{14828547347440118ad7de6d2eecf447,

title = "No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. Japan Adult Leukemia Study Group.",

author = "Mitsune Tanimoto",

year = "1999",

language = "English",

volume = "70",

pages = "97--104",

journal = "Int J Hematol",

number = "(2)",

}

TY - JOUR

T1 - No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. Japan Adult Leukemia Study Group.

AU - Tanimoto, Mitsune

PY - 1999

Y1 - 1999

M3 - Article

VL - 70

SP - 97

EP - 104

JO - Int J Hematol

JF - Int J Hematol

IS - (2)

ER -